Abstract
Lung cancer is a leading cause of death in both men and women, with over 1,000,000 new cases diagnosed worldwide annually and a 5-year survival rate of only 14%, a figure that has improved little in the past thirty years. This poor prognosis suggests a need for novel approaches for the treatment and prevention of lung cancer. The reninangiotensin system is an established, primary regulator of blood pressure, homeostasis, and natriuresis; however, compelling evidence indicates that the angiotensin peptides also play a role in cell proliferation and inflammation. Angiotensin II is a vasoconstrictor, a mitogen, and an angiogenic factor, while angiotensin-(1-7) has vasodilator, antiproliferative, and anti-angiogenic properties. This review focuses on studies examining the renin-angiotensin system in pulmonary cancers and whether clinical intervention of this pathway may serve as an effective chemotherapeutic and/or chemopreventive modality for lung cancer.
Keywords: Renin-angiotensin system, angiotensin, lung cancer, pulmonary cancer, angiotensin-(1-7), angiotensin converting enzyme, angiogenesis, angiotensin receptor blocker, Angiotensin Peptides, plasminogen activated inhibitor, –, 1, vascular endothelial growth factor, cyclooxygenase 2
Current Cancer Drug Targets
Title: Angiotensin Peptides and Lung Cancer
Volume: 11 Issue: 4
Author(s): P. E. Gallagher, K. Cook, D. Soto-Pantoja, J. Menon and E. A. Tallant
Affiliation:
Keywords: Renin-angiotensin system, angiotensin, lung cancer, pulmonary cancer, angiotensin-(1-7), angiotensin converting enzyme, angiogenesis, angiotensin receptor blocker, Angiotensin Peptides, plasminogen activated inhibitor, –, 1, vascular endothelial growth factor, cyclooxygenase 2
Abstract: Lung cancer is a leading cause of death in both men and women, with over 1,000,000 new cases diagnosed worldwide annually and a 5-year survival rate of only 14%, a figure that has improved little in the past thirty years. This poor prognosis suggests a need for novel approaches for the treatment and prevention of lung cancer. The reninangiotensin system is an established, primary regulator of blood pressure, homeostasis, and natriuresis; however, compelling evidence indicates that the angiotensin peptides also play a role in cell proliferation and inflammation. Angiotensin II is a vasoconstrictor, a mitogen, and an angiogenic factor, while angiotensin-(1-7) has vasodilator, antiproliferative, and anti-angiogenic properties. This review focuses on studies examining the renin-angiotensin system in pulmonary cancers and whether clinical intervention of this pathway may serve as an effective chemotherapeutic and/or chemopreventive modality for lung cancer.
Export Options
About this article
Cite this article as:
E. Gallagher P., Cook K., Soto-Pantoja D., Menon J. and A. Tallant E., Angiotensin Peptides and Lung Cancer, Current Cancer Drug Targets 2011; 11 (4) . https://dx.doi.org/10.2174/156800911795538048
DOI https://dx.doi.org/10.2174/156800911795538048 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Insights into the Biological Evaluation of Pterocarpanquinones and Carbapterocarpans with Anti-tumor Activity against MDR Leukemias
Anti-Cancer Agents in Medicinal Chemistry Editorial [ Obesity and the Lung Guest Editors: Neil S. Cherniack and E. Paul Cherniack ]
Current Respiratory Medicine Reviews Cetuximab: Its Use in Combination with Radiation Therapy and Chemotherapy in the Multimodality Treatment of Head and Neck Cancer
Recent Patents on Anti-Cancer Drug Discovery Cetuximab, A Chimeric Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in Colorectal Cancer Treatment
Current Cancer Therapy Reviews Vitamin D Insufficiency and Diabetes Risks
Current Drug Targets Antitumour Activity of Muricatacin Isomers and its Derivatives in Human Colorectal Carcinoma Cell HCT116
Anti-Cancer Agents in Medicinal Chemistry The Nature of Immunological Reaction in the Peripheral Airways of Cigarette Smokers
Current Respiratory Medicine Reviews Berberine as a Promising Safe Anti-Cancer Agent- Is there a Role for Mitochondria?
Current Drug Targets Renal Cell Cancer and Positron Emission Tomography- an Evolving Diagnostic and Therapeutic Relationship
Current Medical Imaging Antioxidant Food Supplements and Obesity-Related Inflammation
Current Medicinal Chemistry The Adipose Tissue as a Source of Vasoactive Factors
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Herb-drug Interactions Involving Drug Metabolizing Enzymes and Transporters
Current Drug Metabolism Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review
Reviews on Recent Clinical Trials Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design A New Approach for β-cyclodextrin Conjugated Drug Delivery System in Cancer Therapy
Current Drug Delivery Target Driven Preclinical Screening for New Antimitotic Chemotherapy Agents
Current Topics in Medicinal Chemistry MEK Inhibition Increases Lapatinib Sensitivity Via Modulation of FOXM1
Current Medicinal Chemistry HIV-1 Vpr: A Closer Look at the Multifunctional Protein from the Structural Perspective
Current HIV Research Application and Interpretation of Genome-Wide Association (GWA) Studies for Informing Pharmacogenomic Research - Examples from the Field of Age-Related Macular Degeneration
Current Molecular Medicine Antitumor Carbazoles
Anti-Cancer Agents in Medicinal Chemistry